Opinion

Video

Cost-Effective Medication Access in Demodex Blepharitis Treatment

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.

This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.

Demodex blepharitis is the leading reason that patients visit eye physicians, making up 40% to 50% of eye care professional appointments. Many patients are misdiagnosed and mistreated for aqueous-deficient dry eye with expensive immunomodulators instead of given the correct Demodex blepharitis diagnosis. Correct diagnosis and treatment with Xdemvy(lotilaner ophthalmic solution) significantly cuts costs.

Once diagnosed, Demodex blepharitis responds well to treatment. Lotilaner is a safe and effective 6-week, twice-daily course that improves ocular surface disease for at least 1 year, showing long-term stability for this previously unmanaged chronic condition.

It is important that patients understand Demodex pathogenesis because an eyelash mite infestation, in addition to clinical outcomes, usually motivates treatment adherence.

Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.

Related Videos
Screenshot of an interview with Amir Ali, PharmD, BCOP
1 expert in this video
1 expert in this video
Dr Cesar Davila-Chapa
1 expert in this video
1 expert in this video
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo